- Autonomix Medical (AMIX, Financial) successfully completes its first-in-human proof-of-concept trial (PoC 1) demonstrating significant pain reduction.
- The company plans to begin a market expansion study (PoC 2) in Q2 2025, focusing on additional visceral cancers and early-stage pancreatic cancer.
- The innovative technology employs transvascular energy to ablate problematic nerves, aiming to mitigate cancer-related pain.
Autonomix Medical, Inc. (AMIX), a leader in medical device innovation, recently participated in a Virtual Investor "What This Means" segment. The event featured Chief Medical Officer Dr. Robert Schwartz, who discussed two significant milestones for the company: completing the first phase of their first-in-human proof-of-concept trial (PoC 1) and plans for the subsequent market expansion study (PoC 2).
The PoC 1 trial highlighted a clinically meaningful reduction in pain for pancreatic cancer patients by utilizing cutting-edge transvascular energy technology to target problematic nerves. This advancement marks a pivotal step for Autonomix Medical, as the company propels forward into the next phase of research and development.
Set to commence in the second quarter of 2025, the PoC 2 trial will investigate the effectiveness of the technology in treating pain associated with additional visceral cancers and earlier-stage pancreatic cancer. This trial aims to expand the application of Autonomix's technology, potentially offering new hope for cancer patients experiencing severe pain.
As Autonomix Medical progresses, their pioneering platform continues to leverage a catheter-based microchip sensing array capable of detecting and differentiating neural signals with unprecedented sensitivity. This advancement holds the promise of transforming the diagnosis and treatment of peripheral nervous system diseases, paving the way for a wide array of future medical applications.
